FDA approves Glaxo's GLP-1

Share this article:

GlaxoSmithKline's weekly GLP-1 diabetes injection has been approved. The FDA made the announcement Tuesday morning. The type-2 diabetes drug, known in past coverage as albiglutide, is officially called Tanzeum.

The FDA was initially set to review the drug in January but said last August that it needed more time to review “information submitted by GSK in response to the [FDA's] requests.”

The approval puts GSK's new drug in a fight for patients whose choices include Novo's Victoza and AstraZeneca's Byetta/Bydureon. BMS ceded it's interest in Byetta/Bydureon last year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters